U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

MedGen UID:
1617968
•Concept ID:
C4520721
•
Neoplastic Process
Synonyms: Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent Cutaneous T-Cell Non-Hodgkin's Lymphoma; Recurrent Skin T-Cell Lymphoma; Recurrent T-Cell Lymphoma of Skin; Recurrent T-Cell Lymphoma of the Skin; Relapsed Cutaneous T-Cell Lymphoma; Relapsed Skin T-Cell Lymphoma; Relapsed T-Cell Lymphoma of Skin; Relapsed T-Cell Lymphoma of the Skin

Definition

The reemergence of primary cutaneous T-cell non-Hodgkin lymphoma after a period of remission. [from NCI]

Professional guidelines

PubMed

Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions.
Chu S, Michelle L, Ekelem C, Sung CT, Rojek N, Mesinkovska NA
Arch Dermatol Res 2021 Aug;313(6):391-430. Epub 2020 Nov 5 doi: 10.1007/s00403-020-02152-4. PMID: 33151346
Pruritus in Cutaneous T-Cell Lymphoma and Its Management.
Serrano L, Martinez-Escala ME, Zhou XA, Guitart J
Dermatol Clin 2018 Jul;36(3):245-258. doi: 10.1016/j.det.2018.02.011. PMID: 29929596
Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment.
Cerroni L
Semin Cutan Med Surg 2018 Mar;37(1):2-10. doi: 10.12788/j.sder.2018.002. PMID: 29719014

Recent clinical studies

Etiology

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group
Lancet Haematol 2022 Nov;9(11):e833-e843. Epub 2022 Oct 10 doi: 10.1016/S2352-3026(22)00245-9. PMID: 36228643
Genetic and epigenetic insights into cutaneous T-cell lymphoma.
Tensen CP, Quint KD, Vermeer MH
Blood 2022 Jan 6;139(1):15-33. doi: 10.1182/blood.2019004256. PMID: 34570882
New developments in non-Hodgkin lymphoid malignancies.
Ganapathi KA, Brown LE, Prakash S, Bhargava P
Pathology 2021 Apr;53(3):349-366. Epub 2021 Mar 5 doi: 10.1016/j.pathol.2021.01.002. PMID: 33685720
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators
Lancet Oncol 2018 Sep;19(9):1192-1204. Epub 2018 Aug 9 doi: 10.1016/S1470-2045(18)30379-6. PMID: 30100375
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group
Lancet 2017 Aug 5;390(10094):555-566. Epub 2017 Jun 7 doi: 10.1016/S0140-6736(17)31266-7. PMID: 28600132

Diagnosis

Cutaneous T-cell lymphoma: diagnosing subtypes and the challenges.
Hague C, Farquharson N, Menasce L, Parry E, Cowan R
Br J Hosp Med (Lond) 2022 Apr 2;83(4):1-7. Epub 2022 Apr 14 doi: 10.12968/hmed.2021.0149. PMID: 35506718
How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
Sethi TK, Montanari F, Foss F, Reddy N
Br J Haematol 2021 Nov;195(3):352-364. Epub 2021 May 14 doi: 10.1111/bjh.17458. PMID: 33987825
Lymphomatoid papulosis.
Sica A, Vitiello P, Sorriento A, Ronchi A, Calogero A, Sagnelli C, Troiani T, Fasano M, Dodaro CA, Franco R, Casale B, Santangelo M, Ciccozzi M, Ciardiello F, Argenziano G, Moscarella E
Minerva Med 2020 Apr;111(2):166-172. Epub 2020 Jan 20 doi: 10.23736/S0026-4806.19.06395-X. PMID: 31958921
Adult-Onset Atopic Dermatitis.
Silverberg JI
J Allergy Clin Immunol Pract 2019 Jan;7(1):28-33. doi: 10.1016/j.jaip.2018.09.029. PMID: 30598180
Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment.
Cerroni L
Semin Cutan Med Surg 2018 Mar;37(1):2-10. doi: 10.12788/j.sder.2018.002. PMID: 29719014

Therapy

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group
Lancet Haematol 2022 Nov;9(11):e833-e843. Epub 2022 Oct 10 doi: 10.1016/S2352-3026(22)00245-9. PMID: 36228643
How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
Sethi TK, Montanari F, Foss F, Reddy N
Br J Haematol 2021 Nov;195(3):352-364. Epub 2021 May 14 doi: 10.1111/bjh.17458. PMID: 33987825
Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions.
Chu S, Michelle L, Ekelem C, Sung CT, Rojek N, Mesinkovska NA
Arch Dermatol Res 2021 Aug;313(6):391-430. Epub 2020 Nov 5 doi: 10.1007/s00403-020-02152-4. PMID: 33151346
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators
Lancet Oncol 2018 Sep;19(9):1192-1204. Epub 2018 Aug 9 doi: 10.1016/S1470-2045(18)30379-6. PMID: 30100375
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group
Lancet 2017 Aug 5;390(10094):555-566. Epub 2017 Jun 7 doi: 10.1016/S0140-6736(17)31266-7. PMID: 28600132

Prognosis

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group
Lancet Haematol 2022 Nov;9(11):e833-e843. Epub 2022 Oct 10 doi: 10.1016/S2352-3026(22)00245-9. PMID: 36228643
Cutaneous T-cell lymphoma: diagnosing subtypes and the challenges.
Hague C, Farquharson N, Menasce L, Parry E, Cowan R
Br J Hosp Med (Lond) 2022 Apr 2;83(4):1-7. Epub 2022 Apr 14 doi: 10.12968/hmed.2021.0149. PMID: 35506718
Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma.
Song X, Chang S, Seminario-Vidal L, de Mingo Pulido A, Tordesillas L, Song X, Reed RA, Harkins A, Whiddon S, Nguyen JV, Segura CM, Zhang C, Yoder S, Sayegh Z, Zhao Y, Messina JL, Harro CM, Zhang X, Conejo-Garcia JR, Berglund A, Sokol L, Zhang J, Rodriguez PC, Mulé JJ, Futreal AP, Tsai KY, Chen PL
Cancer Discov 2022 May 2;12(5):1294-1313. doi: 10.1158/2159-8290.CD-21-1207. PMID: 35247891Free PMC Article
How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
Sethi TK, Montanari F, Foss F, Reddy N
Br J Haematol 2021 Nov;195(3):352-364. Epub 2021 May 14 doi: 10.1111/bjh.17458. PMID: 33987825
Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment.
Cerroni L
Semin Cutan Med Surg 2018 Mar;37(1):2-10. doi: 10.12788/j.sder.2018.002. PMID: 29719014

Clinical prediction guides

Primary cutaneous B-cell lymphoma: A single-center 5-year experience.
Jacob LA, Asati V, Lakshmaiah KC, Govind BK, Lokanatha D, Babu SM, Lokesh KN, Rudresh AH, Rajeev LK, Mulchandani NJ, Anand A, Koppaka D, Mysore SN
Indian J Cancer 2018 Apr-Jun;55(2):134-137. doi: 10.4103/ijc.IJC_418_17. PMID: 30604723
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators
Lancet Oncol 2018 Sep;19(9):1192-1204. Epub 2018 Aug 9 doi: 10.1016/S1470-2045(18)30379-6. PMID: 30100375
Pruritus in Cutaneous T-Cell Lymphoma and Its Management.
Serrano L, Martinez-Escala ME, Zhou XA, Guitart J
Dermatol Clin 2018 Jul;36(3):245-258. doi: 10.1016/j.det.2018.02.011. PMID: 29929596
Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT, Lewis DJ, Duvic M
Expert Rev Hematol 2017 Sep;10(9):757-760. Epub 2017 Aug 21 doi: 10.1080/17474086.2017.1361819. PMID: 28756726
Systemic and primary cutaneous anaplastic large cell lymphomas.
Kadin ME, Carpenter C
Semin Hematol 2003 Jul;40(3):244-56. doi: 10.1016/s0037-1963(03)00138-0. PMID: 12876673

Recent systematic reviews

Woringer-Kolopp disease (localized pagetoid reticulosis): a systematic review.
Osto M, Afify O, Musa A, Ahmed U, Rehman R, Mehregan D
Int J Dermatol 2023 Mar;62(3):312-321. Epub 2022 Apr 29 doi: 10.1111/ijd.16224. PMID: 35485962
Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions.
Chu S, Michelle L, Ekelem C, Sung CT, Rojek N, Mesinkovska NA
Arch Dermatol Res 2021 Aug;313(6):391-430. Epub 2020 Nov 5 doi: 10.1007/s00403-020-02152-4. PMID: 33151346
Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis.
Iqbal M, Reljic T, Ayala E, Sher T, Murthy H, Roy V, Foran J, Tun H, Kumar A, Kharfan-Dabaja MA
Biol Blood Marrow Transplant 2020 Jan;26(1):76-82. Epub 2019 Sep 5 doi: 10.1016/j.bbmt.2019.08.019. PMID: 31494227
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, Olsen E, Kim YH, Dummer R, Pimpinelli N, Whittaker S, Hodak E, Cerroni L, Berti E, Horwitz S, Prince HM, Guitart J, Estrach T, Sanches JA, Duvic M, Ranki A, Dreno B, Ostheeren-Michaelis S, Knobler R, Wood G, Willemze R
Blood 2011 Oct 13;118(15):4024-35. Epub 2011 Aug 12 doi: 10.1182/blood-2011-05-351346. PMID: 21841159Free PMC Article
Molecular cytogenetic characterization of Sézary syndrome.
Mao X, Lillington DM, Czepulkowski B, Russell-Jones R, Young BD, Whittaker S
Genes Chromosomes Cancer 2003 Mar;36(3):250-60. doi: 10.1002/gcc.10152. PMID: 12557225

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...